Prospects for Bayer’s oral Factor XIa inhibitor asundexian have improved markedly after a phase 3 trial in secondary stroke prevention.
Investors buy up stocks in biggest follow-on offering day in biotech history
A record-setting $3.2 billion in biotech follow-on stock offerings were sold over the last 24 hours, another indication of public investors’ appetite for the sector.


